MELBOURNE, Australia, Sept. 3 /PRNewswire/ -- Cytopia Limited's (ASX: CYT)
Investigational New Drug Application (IND) for CYT387 has passed US Food and
Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2
kinase inhibitor designed to treat various haematological disorders. The
company's IND application is now active and Cytopia is able to proceed with
clinical trials for CYT387 in the United States.
